Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis

Therapeutic Advances in Neurological Disorders
Uwe K ZettlRobert Patejdl

Abstract

Spasticity, one of the main symptoms of multiple sclerosis (MS), can affect more than 80% of MS patients during the course of their disease and is often not treated adequately. δ-9-Tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray is a plant-derived, standardized cannabinoid-based oromucosal spray medicine for add-on treatment of moderate to severe, resistant multiple sclerosis-induced spasticity. This article reviews the current evidence for the efficacy and safety, with dizziness and fatigue as the most common treatment-related adverse events, being mostly mild to moderate in severity. Results from both randomized controlled phase III studies involving about,1600 MS patients or 1500 patient-years and recently published studies on everyday clinical practice involving more than 1000 patients or more than,1000 patient-years are presented.

References

Jun 8, 1989·The New England Journal of Medicine·R D PennJ S Kroin
Feb 1, 1987·Physical Therapy·R W Bohannon, M B Smith
Jan 20, 2000·Muscle & Nerve·M D Smyth, W J Peacock
Oct 18, 2000·The Cochrane Database of Systematic Reviews·D T ShakespeareM Boggild
Feb 7, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·D BakerV Di Marzo
Feb 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·A Johns
Nov 1, 2001·The Cochrane Database of Systematic Reviews·D T ShakespeareC Young
Mar 7, 2002·JAMA : the Journal of the American Medical Association·Nadia SolowijUNKNOWN Marijuana Treatment Project Research Group
Mar 21, 2003·Neurorehabilitation and Neural Repair·M P BarnesK M McMullen
Oct 30, 2003·The Cochrane Database of Systematic Reviews·D T ShakespeareC Young
Nov 26, 2003·Health Technology Assessment : HTA·S BeardJ Wight
Feb 3, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Louise ArseneaultRobin M Murray
Aug 26, 2004·Multiple Sclerosis : Clinical and Laboratory Research·Joep Killestein, Chris Polman
Oct 9, 2004·Multiple Sclerosis : Clinical and Laboratory Research·M A RizzoT L Vollmer
Apr 29, 2005·International Journal of Clinical Practice·M A WareG W Guy
Jan 13, 2006·British Journal of Pharmacology·Roger G Pertwee
Feb 16, 2006·Journal of Neurology·Christian KabusMartin Winterholler
Jun 6, 2006·Clinical Therapeutics·Heidi J Crayton, Howard S Rossman
Sep 13, 2006·European Neurology·T HenzeUNKNOWN Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society
Sep 14, 2006·Drugs of Today·Jordi Perez
Nov 8, 2006·Multiple Sclerosis : Clinical and Laboratory Research·D T WadeP Robson
Mar 14, 2007·Current Opinion in Lipidology·Vincenzo Di Marzo, Stefania Petrosino
Mar 16, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·C CollinUNKNOWN Sativex Spasticity in MS Study Group
Apr 22, 2008·Expert Opinion on Pharmacotherapy·Jordi Perez, M Victoria Ribera
Sep 2, 2008·Archives of Physical Medicine and Rehabilitation·Thomas D MarcotteJody Corey-Bloom
Feb 20, 2009·British Journal of Pharmacology·Roger G Pertwee
Mar 28, 2009·Journal of Neurology·Peter Flachenecker, Kristin Stuke
Sep 5, 2009·Trends in Pharmacological Sciences·Angelo A IzzoRaphael Mechoulam
Sep 23, 2009·Journal of Neurology, Neurosurgery, and Psychiatry·J F M FleurenA V Nene
Dec 19, 2009·Journal of Neurology, Neurosurgery, and Psychiatry·Katharina S Sunnerhagen
Apr 3, 2010·Clinical Rehabilitation·V L Stevenson
Jun 19, 2010·Multiple Sclerosis : Clinical and Laboratory Research·Derick T WadePaul Duncombe
Jan 1, 2000·Addiction Biology·R G Pertwee

❮ Previous
Next ❯

Citations

May 28, 2016·Expert Opinion on Investigational Drugs·Ricardo P GarayPierre-Michel Llorca
Mar 8, 2018·The Cochrane Database of Systematic Reviews·Martin MückeWinfried Häuser
Sep 20, 2018·Multiple Sclerosis : Clinical and Laboratory Research·Paulus Stefan RommerUwe Klaus Zettl
Jan 23, 2020·Expert Opinion on Drug Safety·Niklas FrahmUwe Klaus Zettl
Jul 15, 2020·Journal of Neurology, Neurosurgery, and Psychiatry·Clara Grazia ChisariFrancesco Patti
Aug 16, 2019·Therapeutic Advances in Medical Oncology·Amber S KlecknerLuke J Peppone
Apr 24, 2020·Cannabis and Cannabinoid Research·James M Nichols, Barbara L F Kaplan
Oct 28, 2017·Nature Reviews. Drug Discovery·Alexander S HauserDavid E Gloriam
Dec 22, 2020·British Journal of Pharmacology·Joseph L Damstra-OddyRobin S B Williams
Nov 14, 2020·The American Journal of Medicine·Ahmed K PashaAiden Abidov
Apr 22, 2021·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Mark OppeJuan M Ramos-Goñi
May 26, 2021·Cannabis and Cannabinoid Research·Xandy Melissa Rodríguez MesaSandra Paola Santander González
Jun 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ersilia NigroAurora Daniele
Jul 30, 2021·ImmunoTargets and Therapy·Valeria GiorgiPiercarlo Sarzi-Puttini

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

MOVE

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.